rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-590-597rsp-3654Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESИксекизумаб в терапии псориатического артритаIxekizumab in the treatment of psoriatic arthritishttps://orcid.org/0000-0001-5968-2403КорсаковаЮ. Л.KorsakovaYu. L.

Корсакова Юлия Леонидовна 

115522, Москва, Каширское шоссе, 34а

Yulia L. Korsakova 

115522, Moscow, Kashirskoye Highway, 34A

yulkorsakova@bk.ruhttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34а

Tatiana V. Korotaeva 

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202426122024626590597Copyright © Корсакова Ю.Л., Коротаева Т.В., 20242024Корсакова Ю.Л., Коротаева Т.В.Korsakova Y.L., Korotaeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3654

Псориатический артрит (ПсА) характеризуется сочетанием скелетно-мышечных и внесуставных проявлений, таких как периферический артрит, поражение аксиальных структур, дактилит, энтезит, увеит, воспалительные заболевания кишечника, псориаз (Пс). В настоящее время достигнут большой прогресс в изучении патогенеза ПсА и фармакотерапии этого заболевания. В статье представлены данные по эффективности и безопасности ингибитора интерлейкина 17 иксекизумаба (ИКСЕ). ИКСЕ демонстрирует высокую терапевтическую эффективность в отношении всех клинических проявлений ПсА у большинства больных независимо от сопутствующего приема метотрексата и предшествующего приема генно-инженерных биологических препаратов, наличия кардиометаболической коморбидности. Данный препарат задерживает прогрессирование деструктивных процессов в суставах. ИКСЕ показан пациентам с Пс проблемной локализации: ладонноподошвенным, аногенитальным, волосистой части головы и ногтей.

Psoriatic arthritis (PsA) is characterized by a combination of musculoskeletal and extra-articular manifestations, such as peripheral arthritis, axial disease, dactylitis, enthesitis, uveitis, inflammatory bowel disease, psoriasis (Ps). Currently, great progress has been made in the study of the pathogenesis of PsA and pharmacotherapy of this disease. The article presents data on the efficacy and safety of the IL-17 inhibitor ixekizumab (IXE). IXE demonstrates high therapeutic efficacy against all clinical manifestations of PsA in most patients, regardless of concomitant methotrexate intake and previous intake of biological disease-modifying antirheumatic drugs, the presence of cardiometabolic comorbidity. This drug delays the progression of destructive processes in the joints. IXE is indicated for patients with Ps of problematic localization: palmar-plantar, anogenital, scalp and nails.

иксекизумабингибитор интерлейкина 17псориатический артритпсориазixekizumabinterleukin 17 inhibitorpsoriatic arthritispsoriasisИсследование (анализ данных эффективности и безопасности препарата) проводилось в рамках выполнения фундаментальной научной темы «Совершенствование диагностики и фармакотерапии спондилоартритов на основании сравнительных результатов изучения (в том числе молекулярно-биологических, молекулярно-генетических, клинико-визуализационных) факторов прогрессирования заболевания и уровня качества жизни больных», утвержденной ученым советом ФГНБУ НИИР им. В.А. Насоновой, регистрационный номер темы в ЕГИСУ 1021051503111-9.ReferencesCampanholo CB, Maharaj AB, Corp N, Bell S, Costa L, de Vlam K, et al. Management of psoriatic arthritis in patients with comorbidities: An updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023;50(3):426-432. doi: 10.3899/jrheum.220310Campanholo CB, Maharaj AB, Corp N, Bell S, Costa L, de Vlam K, et al. Management of psoriatic arthritis in patients with comorbidities: An updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023;50(3):426-432. doi: 10.3899/jrheum.220310Корсакова ЮЛ, Коротаева ТВ, Логинова ЕЮ, Губарь ЕЕ, Василенко ЕА, Василенко АА, и др. Распространенность коморбидных и сопутствующих заболеваний при псориатическом артрите по данным Общероссийского регистра больных псориатическим артритом. Научно-практическая ревматология. 2021;59(3):275-281. doi: 10.47360/1995-4484-2021-275-281Korsakova YuL, Korotaeva TV, Loginova EYu, Gubar EE, Vasilenko EA, Vasilenko AA, et al. The prevalence of comorbid and concomitant diseases in psoriatic arthritis patients, data from Russian register. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):275-281 (In Russ.). doi: 10.47360/1995-4484-2021-275-281Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86. doi: 10.14412/1995-4484-2017-68-86Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.). doi: 10.14412/1995-4484-2017-68-86McGonagle D, David P, Macleod T, Watad A. Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis. Nat Rev Rheumatol. 2023;19(12):818-827. doi: 10.1038/s41584-023-01038-9McGonagle D, David P, Macleod T, Watad A. Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis. Nat Rev Rheumatol. 2023;19(12):818-827. doi: 10.1038/s41584-023-01038-9McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892-906. doi: 10.1016/j. immuni.2019.03.021McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892-906. doi: 10.1016/j. immuni.2019.03.021Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-719. doi: 10.1136/ard-2024-225531Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-719. doi: 10.1136/ard-2024-225531Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39- 50. doi: 10.2147/JIR.S100940Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39- 50. doi: 10.2147/JIR.S100940Инструкция по медицинскому применению лекарственного препарата Талс® (МНН: иксекизумаб), ЛП-005200. . URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=162d7700-9071-4af4-bfaa-4e5097125870 (Accessed: 13th September 2024).Instructions for medical use of the medicinal product Tals® (INN: ixekizumab), LP-005200. (In Russ.). URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=162d7700-9071-4af4-bfaa-4e5097125870 (Accessed: 13th September 2024).Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al.; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al.; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al.; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al.; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al.; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al.; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: Integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):38. doi: 10.1186/s13075-019-1831-0Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: Integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):38. doi: 10.1186/s13075-019-1831-0van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367-377. doi: 10.3899/jrheum.170429van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367-377. doi: 10.3899/jrheum.170429Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, et al. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford). 2018;57(10):1777- 1788. doi: 10.1093/rheumatology/key161Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, et al. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford). 2018;57(10):1777- 1788. doi: 10.1093/rheumatology/key161Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, et al. Ixekizumab treatment of biologicnaïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774-2784. doi: 10.1093/rheumatology/kez684Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, et al. Ixekizumab treatment of biologicnaïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774-2784. doi: 10.1093/rheumatology/kez684Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57(11):2001-2011. doi: 10.1093/rheumatology/key182Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57(11):2001-2011. doi: 10.1093/rheumatology/key182Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, et al. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin Exp Rheumatol. 2019;37(4):566-574.Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, et al. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin Exp Rheumatol. 2019;37(4):566-574.Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: Final results by week 52. AnnRheum Dis. 2020;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: Final results by week 52. AnnRheum Dis. 2020;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: An integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14. doi: 10.1186/s13075-020-2099-0Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: An integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14. doi: 10.1186/s13075-020-2099-0Kameda H, Hagimori K, Morisaki Y, Holzkämper T, Konomi A, Dobashi H. Ixekizumab efficacy in patients with severe peripheral psoriatic arthritis: A post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study (SPIRIT-P1). Rheumatol Ther. 2023;10(6):1683-1703. doi: 10.1007/s40744-023-00605-6Kameda H, Hagimori K, Morisaki Y, Holzkämper T, Konomi A, Dobashi H. Ixekizumab efficacy in patients with severe peripheral psoriatic arthritis: A post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study (SPIRIT-P1). Rheumatol Ther. 2023;10(6):1683-1703. doi: 10.1007/s40744-023-00605-6Deodhar A, Gladman D, Bolce R, Sandoval D, Park SY, Leage SL, et al. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005. doi: 10.1177/1759720X231189005Deodhar A, Gladman D, Bolce R, Sandoval D, Park SY, Leage SL, et al. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005. doi: 10.1177/1759720X231189005Yao CJ, Lebwohl MG. Onset of action of antipsoriatic drugs for moderate-to-severe plaque psoriasis: An update. J Drugs Dermatol. 2019;18(3):229-233.Yao CJ, Lebwohl MG. Onset of action of antipsoriatic drugs for moderate-to-severe plaque psoriasis: An update. J Drugs Dermatol. 2019;18(3):229-233.Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et al.; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047-1058. doi: 10.1111/bjd.19509Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et al.; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047-1058. doi: 10.1111/bjd.19509Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, et al. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360-368. doi: 10.1016/j.jaad.2020.11.022Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, et al. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360-368. doi: 10.1016/j.jaad.2020.11.022Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824-830.e2. doi: 10.1016/j.jaad.2018.05.032Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824-830.e2. doi: 10.1016/j.jaad.2018.05.032Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, et al. Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: Real-life experience from a resistant population. Biologics. 2021;15:463-470. doi: 10.2147/BTT.S326792Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, et al. Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: Real-life experience from a resistant population. Biologics. 2021;15:463-470. doi: 10.2147/BTT.S326792Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. doi: 10.1016/j.semarthrit.2022.151979Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. doi: 10.1016/j.semarthrit.2022.151979Miller J, Puravath AP, Orbai AM. Ixekizumab for psoriatic arthritis: Safety, efficacy, and patient selection. J Inflamm Res. 2021;14:6975-6991. doi: 10.2147/JIR.S229752Miller J, Puravath AP, Orbai AM. Ixekizumab for psoriatic arthritis: Safety, efficacy, and patient selection. J Inflamm Res. 2021;14:6975-6991. doi: 10.2147/JIR.S229752Deodhar AA, Combe B, Accioly AP, Bolce R, Zhu D, Gellett AM, et al. Safety of ixekizumab in patients with psoriatic arthritis: Data from four clinical trials with over 2000 patient-years of exposure. Ann Rheum Dis. 2022;81(7):944-950. doi: 10.1136/annrheumdis-2021-222027Deodhar AA, Combe B, Accioly AP, Bolce R, Zhu D, Gellett AM, et al. Safety of ixekizumab in patients with psoriatic arthritis: Data from four clinical trials with over 2000 patient-years of exposure. Ann Rheum Dis. 2022;81(7):944-950. doi: 10.1136/annrheumdis-2021-222027Food and Drug Administration. Ixekizumab label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf (Accessed: 6 July 2021).Food and Drug Administration. Ixekizumab label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf (Accessed: 6 July 2021).Combe B, Tsai TF, Huffstutter JE, Sprabery AT, Lin CY, Park SY, et al. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: Week 52 results from SpiritP1 and Spirit-P2 studies. Arthritis Res Ther. 2021;23(1):41. doi: 10.1186/s13075-020-02388-5Combe B, Tsai TF, Huffstutter JE, Sprabery AT, Lin CY, Park SY, et al. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: Week 52 results from SpiritP1 and Spirit-P2 studies. Arthritis Res Ther. 2021;23(1):41. doi: 10.1186/s13075-020-02388-5

The authors declare that there are no conflicts of interest present.